Logo image of SANA

SANA BIOTECHNOLOGY INC (SANA) Stock Price, Quote, News and Overview

NASDAQ:SANA - Nasdaq - US7995661045 - Common Stock - Currency: USD

2.17  -0.1 (-4.41%)

After market: 2.24 +0.07 (+3.23%)

SANA Quote, Performance and Key Statistics

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (5/30/2025, 8:00:01 PM)

After market: 2.24 +0.07 (+3.23%)

2.17

-0.1 (-4.41%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High8.16
52 Week Low1.26
Market Cap489.47M
Shares225.56M
Float205.60M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO02-04 2021-02-04


SANA short term performance overview.The bars show the price performance of SANA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

SANA long term performance overview.The bars show the price performance of SANA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of SANA is 2.17 USD. In the past month the price increased by 14.21%. In the past year, price decreased by -71.07%.

SANA BIOTECHNOLOGY INC / SANA Daily stock chart

SANA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 328.74B
AMGN AMGEN INC 13.88 154.96B
GILD GILEAD SCIENCES INC 14.22 136.93B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.52B
REGN REGENERON PHARMACEUTICALS 11.06 52.94B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.71B
ARGX ARGENX SE - ADR 99.7 35.00B
ONC BEONE MEDICINES LTD-ADR 6.29 26.55B
BNTX BIONTECH SE-ADR N/A 23.03B
NTRA NATERA INC N/A 21.54B
BIIB BIOGEN INC 8.2 19.02B
UTHR UNITED THERAPEUTICS CORP 12.72 14.38B

About SANA

Company Profile

SANA logo image Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

Company Info

SANA BIOTECHNOLOGY INC

188 East Blaine Street, Suite 400

Seattle WASHINGTON 98102 US

CEO: Steven D. Harr

Employees: 328

SANA Company Website

SANA Investor Relations

Phone: 12067017914

SANA BIOTECHNOLOGY INC / SANA FAQ

What is the stock price of SANA BIOTECHNOLOGY INC today?

The current stock price of SANA is 2.17 USD. The price decreased by -4.41% in the last trading session.


What is the ticker symbol for SANA BIOTECHNOLOGY INC stock?

The exchange symbol of SANA BIOTECHNOLOGY INC is SANA and it is listed on the Nasdaq exchange.


On which exchange is SANA stock listed?

SANA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SANA BIOTECHNOLOGY INC stock?

14 analysts have analysed SANA and the average price target is 9.69 USD. This implies a price increase of 346.54% is expected in the next year compared to the current price of 2.17. Check the SANA BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SANA BIOTECHNOLOGY INC worth?

SANA BIOTECHNOLOGY INC (SANA) has a market capitalization of 489.47M USD. This makes SANA a Small Cap stock.


How many employees does SANA BIOTECHNOLOGY INC have?

SANA BIOTECHNOLOGY INC (SANA) currently has 328 employees.


What are the support and resistance levels for SANA BIOTECHNOLOGY INC (SANA) stock?

SANA BIOTECHNOLOGY INC (SANA) has a support level at 1.78 and a resistance level at 2.28. Check the full technical report for a detailed analysis of SANA support and resistance levels.


Should I buy SANA BIOTECHNOLOGY INC (SANA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SANA BIOTECHNOLOGY INC (SANA) stock pay dividends?

SANA does not pay a dividend.


When does SANA BIOTECHNOLOGY INC (SANA) report earnings?

SANA BIOTECHNOLOGY INC (SANA) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of SANA BIOTECHNOLOGY INC (SANA)?

SANA BIOTECHNOLOGY INC (SANA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).


What is the Short Interest ratio of SANA BIOTECHNOLOGY INC (SANA) stock?

The outstanding short interest for SANA BIOTECHNOLOGY INC (SANA) is 19.5% of its float. Check the ownership tab for more information on the SANA short interest.


SANA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to SANA. When comparing the yearly performance of all stocks, SANA is a bad performer in the overall market: 93.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SANA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SANA. SANA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SANA Financial Highlights

Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 40.14% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -46.84%
ROE -99.81%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%57.14%
Sales Q2Q%N/A
EPS 1Y (TTM)40.14%
Revenue 1Y (TTM)N/A

SANA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to SANA. The Buy consensus is the average rating of analysts ratings from 14 analysts.


Ownership
Inst Owners94.42%
Ins Owners8.68%
Short Float %19.5%
Short Ratio11.16
Analysts
Analysts84.29
Price Target9.69 (346.54%)
EPS Next Y32.61%
Revenue Next YearN/A